GSK Announces FDA Advisory Committee Meeting to Review Belantamab Mafodotin for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma

London UK - 19 June 2020 -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) will convene a meeting of the Oncologic Drugs Advisory Committee (ODAC) to review data supporting the company’s...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials